MAXCYTE INC. - COMMON STOCK

MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences

09 فبراير 2024 08:05:00 بحسب Nasdaq GlobeNewswire

MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers

30 يناير 2024 08:05:00 بحسب Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs

23 يناير 2024 08:05:00 بحسب Nasdaq GlobeNewswire

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results

08 يناير 2024 16:05:00 بحسب Nasdaq GlobeNewswire

MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline

03 يناير 2024 08:05:00 بحسب Nasdaq GlobeNewswire

MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director

02 يناير 2024 02:00:00 بحسب Nasdaq GlobeNewswire

MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023

11 ديسمبر 2023 16:05:00 بحسب Nasdaq GlobeNewswire

MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member

16 نوفمبر 2023 08:05:00 بحسب Nasdaq GlobeNewswire

MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance

08 نوفمبر 2023 16:05:01 بحسب Nasdaq GlobeNewswire

MaxCyte to Participate in Two Upcoming Investor Conferences

06 نوفمبر 2023 16:05:00 بحسب Nasdaq GlobeNewswire

MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance

04 أكتوبر 2023 16:05:00 بحسب Nasdaq GlobeNewswire

MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing

06 سبتمبر 2023 08:05:00 بحسب Nasdaq GlobeNewswire

MaxCyte to Participate in Baird Global Healthcare Conference

05 سبتمبر 2023 08:05:00 بحسب Nasdaq GlobeNewswire

MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance

09 أغسطس 2023 16:05:01 بحسب Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients

01 أغسطس 2023 08:05:51 بحسب Nasdaq GlobeNewswire

MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023

13 يوليو 2023 08:05:00 بحسب Nasdaq GlobeNewswire

MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies

10 يوليو 2023 08:05:00 بحسب Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Lyell Immunopharma

06 يوليو 2023 08:05:05 بحسب Nasdaq GlobeNewswire

MaxCyte to Participate in Upcoming Investor Conferences

01 يونيو 2023 16:05:00 بحسب Nasdaq GlobeNewswire

MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance

10 مايو 2023 16:05:01 بحسب Nasdaq GlobeNewswire